Relationship between metabolic syndrome and cognition in patients with schizophrenia

Schizophrenia Research

Volumn 142, Issue 1-3, 2012, Pages 171-176

  Lindenmayer, Jean Pierre ^a,b,c   Khan, Anzalee ^a,d   Kaushik, Saurabh ^a,b,c   Thanju, Amod ^a,c   Praveen, Rajalakshmi ^c   Hoffman, Lisa ^a   Cherath, Lata ^b   Valdez, Gladys ^a   Wance, Deborah ^a  

^a MANHATTAN PSYCHIATRIC CENTER   (United States)

^b NEW YORK UNIVERSITY   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d ProPhase LLC   (United States)

Author keywords

Cognition; Metabolic syndrome; Schizophrenia; Treatment of metabolic dysfunctions

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; TRIACYLGLYCEROL;

ADULT; AGED; ALERTNESS; ARTICLE; ATTENTION; BODY MASS; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PERFORMANCE; METABOLIC SYNDROME X; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROBLEM SOLVING; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; VELOCITY; WAIST CIRCUMFERENCE; WORKING MEMORY;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; FEMALE; HUMANS; MALE; METABOLIC DISEASES; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; YOUNG ADULT;

EID: 84869883414     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2012.09.019     Document Type: Article

References (39)

1. Alberti K.G., Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 1998, 15(7):539-553.
2. Arvanitakis Z., Wilson R.S., Bienias J.L., Evans D.A., Bennett D.A. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch. Neurol. 2004, 61(5):661-666.
3. Bruehl H., Rueger M., Dziobek I., Sweat V., Tirsi A., Javier E., et al. Hypothalamic-pituitary-adrenal axis dysregulation and memory impairments in type 2 diabetes. J. Clin. Endocrinol. Metab. 2007, 92(7):2439-2445.
4. Buchanan R.W., Davis M., Goff D., Green M.F., Keefe R.S., Leon A.C., et al. A summary of the FDA-NIMH-MATRICS Workshop on Clinical Trial Design for Neurocognitive Drugs for Schizophrenia. Schizophr. Bull. 2005, 31(1):5-19.
5. Casey D.E., Haupt D.W., Newcomer J.W., Henderson D.C., Sernyak M.J., Davidson M., et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J. Clin. Psychiatry 2004, 65(Suppl. 7):4-18.
6. Cohen J. Statistical Power Analysis of the Behavioral Sciences 1988, Academic Press, New York. 2nd ed.
7. Cohn T., Prud'homme D., Streiner D., Kameh H., Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can. J. Psychiatry 2004, 49(11):753-760.
8. Crum R.M., Anthony J.C., Bassett S.S., Folstein M.F. Population-based norms for the Mini-Mental State Examination by age and education level. JAMA 1993, 269(18):2386-2391.
9. Dickinson D., Gold J.M., Dickerson F.B., Medoff D., Dixon L.B. Evidence of exacerbated cognitive deficits in schizophrenia patients with comorbid diabetes. Psychosomatics 2008, 49(2):123-131.
10. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 1975, 12(3):189-198.
11. Fontbonne A., Berr C., Ducimetiere P., Alperovitch A. Changes in cognitive abilities over a 4-year period are unfavorably affected in elderly diabetic subjects: results of The Epidemiology of Vascular Aging Study. Diabetes Care 2001, 24(2):366-370.
12. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the Third National Health and Nutrition Examination Survey. JAMA 2002, 287(3):356-359.
13. Friedman J.I., Wallenstein S., Moshier E., Parrella M., White L., Bowler S., et al. The effects of hypertension and body mass index on cognition in schizophrenia. Am. J. Psychiatry 2010, 167(10):1232-1239.
14. Gold S., Dziobek I., Sweat V., Tirsi A., Rogers K., Bruehl H., et al. Hippocampal damage and memory impairments as possible early brain complications of type 2 diabetes. Diabetologia 2007, 50(4):711-719.
15. Green M.F. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry 1996, 153(3):321-330.
16. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005, 112:2735-2752.
17. Hannesdottir K., Nitkunan A., Charlton R.A., Barrick T.R., MacGregor G.A., Markus H.S. Cognitive impairment and white matter damage in hypertension: a pilot study. Acta Neurol. Scand. 2009, 119(4):261-268.
18. Kalra L., Jackson S.H., Swift C.G. Effect of antihypertensive treatment on psychomotor performance in the elderly. J. Hum. Hypertens. 1993, 7:285-290.
19. Keefe R.S., Perkins D.O., GuHongbinZipursky R.B., Christensen B.K., Lieberman J.A. A longitudinal study of neurocognitive function in individuals at-risk for psychosis. Schizophr. Res. 2006, 88:26-35.
20. Lamberti J.S., Olson D., Crilly J.F., Olivares T., Willliams G.C., Tu X., et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am. J. Psychiatry 2006, 163:1273-1276.
21. Lindenmayer J.P., Nathan A.M., Smith R.C. Hyperglycemia associated with the use of atypical antipsychotics. J. Clin. Psychiatry 2001, 62(Suppl. 23):30-38.
22. Lindenmayer J.P., McGurk S.R., Mueser K.T., Khan A., Wance D., Hoffman L., et al. A randomized controlled trial of cognitive remediation among inpatients with persistent mental illness. Psychiatr. Serv. 2008, 59(3):241-247.
23. McEvoy J.P. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80(1):19-32.
24. Meyer J.M., Nasrallah H.A., McEvoy J.P., Goff D.C., Davis S.M., Chakos M., et al. The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial: clinical comparison of subgroups with and without the metabolic syndrome. Schizophr. Res. 2005, 80:9-18.
25. Meyer J.M., Davis V.G., Goff D.C., McEvoy J.P., Nasrallah H.A., Davis S.M., et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophr. Res. 2008, 101:273-286.
26. NCEP Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults 2001, 285(19):2486-2497. http://www.ncbi.nlm.nih.gov/pubmed/11368702.
27. Newcomer J.W. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005, 19(Suppl. 1):1-93.
28. Pajonk F.G., Wobrock T., Gruber O., Scherk H., Berner D., Kaizl I., et al. Hippocampal plasticity in response to exercise in schizophrenia. Arch. Gen. Psychiatry 2010, 67(2):133-143.
29. Pavlik V.N., Hyman D.J., Doody R. Cardiovascular risk factors and cognitive function in adults 30-59years of age (NHANES III). Neuroepidemiology 2005, 24(1-2):42-50.
30. Ryan J.D., Cohen N.J. Processing and short-term retention of relational information in amnesia. Neuropsychologia 2004, 42(4):497-511.
31. Ryan J.D., Althoff R.R., Whitlow S., Cohen N.J. Amnesia is a deficit in relational memory. Psychol. Sci. 2000, 11(6):454-461.
32. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160(2):284-289.
33. Strachan M.W., Deary I.J., Ewing F.M., Frier B.M. Is type II diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997, 20:438-445.
34. Tournoy J., Lee D.M., Pendleton N., O'Neill T.W., O'Connor D.B., Bartfai G., et al. Association of cognitive performance with the metabolic syndrome and with glycaemia in middle-aged and older European men: the European Male Ageing Study. Diabetes Metab. Res. Rev. 2010, 26(8):668-676.
35. Tzourio C., Anderson C., Chapman N., Woodward M., Neal B., MacMahon S., Chalmers J. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch. Intern. Med. 2003, 163(9):1069-1075.
36. Wilkinson G. WRAT3: Wide Range Achievement Test Administration Manual 1993, Wilmington, DE Wide Range, Inc.
37. Witte A.V., Fobker M., Gellner R., Knecht S., Flöel A. Caloric restriction improves memory in elderly humans. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(4):1255-1260.
38. Yaffe K., Blackwell T., Kanaya A.M., Davidowitz N., Barrett-Connor E., Krueger K. Diabetes impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004, 63(4):658-663.
39. Yau P.L., Javier D.C., Ryan C.M., Tsui W.H., Ardekani B.A., Ten S., Convit A. Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus. Diabetologia 2010, 53(11):2298-2306.